https://blog.creaders.net/u/14263/202208/441781.html 
Conclusions: Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified. 结论： 基于 18 项 COVID-19 伊维菌素随机对照治疗试验的荟萃分析发现，死亡率、临床恢复时间和病毒清除时间显着降低，具有统计学意义。此外，许多对照预防试验的结果表明，经常使用伊维菌素可显着降低感染 COVID-19 的风险。最后，许多伊维菌素分发活动导致全人群发病率和死亡率迅速下降的例子表明，已经确定了一种在 COVID-19 的所有阶段都有效的口服药物。The evidence base for ivermectin against COVID-19To date, the efficacy of ivermectin in COVID-19 has been supported by the following: Since 2012, multiple in vitro studies have demonstrated that Ivermectin inhibits the replication of many viruses, including influenza, Zika, Dengue, and others.9–17Ivermectin inhibits SARS-CoV-2 replication and binding to host tissue through several observed and proposed mechanisms.18Ivermectin has potent anti-inflammatory properties with in vitro data demonstrating profound inhibition of both cytokine production and transcription of nuclear factor-κB (NF-κB), the most potent mediator of inflammation.37–39Ivermectin significantly diminishes viral load and protects against organ damage in multiple animal models when infected with SARS-CoV-2 or similar coronaviruses.31,32Ivermectin prevents transmission and development of COVID-19 disease in those exposed to infected patients.40–45Ivermectin hastens recovery and prevents deterioration in patients with mild to moderate disease treated early after symptoms.45,49–52,61,62Ivermectin hastens recovery and avoidance of ICU admission and death in hospitalized patients.45,51,53,63–66Ivermectin reduces mortality in critically ill patients with COVID-19.45,53,63Ivermectin leads to temporally associated reductions in case fatality rates in regions after ivermectin distribution campaigns.48The safety, availability, and cost of ivermectin are nearly unparalleled given its low incidence of important drug interactions along with only mild and rare side effects observed in almost 40 years of use and billions of doses administered.75The World Health Organization has long included ivermectin on its “List of Essential Medicines.”伊维菌素对抗 COVID-19 的证据基础迄今为止，伊维菌素在 COVID-19 中的疗效得到以下支持： 自 2012 年以来，多项体外研究表明，伊维菌素可抑制多种病毒的复制，包括流感、寨卡病毒、登革热病毒等。9 - 17伊维菌素通过几种观察到和提出的机制抑制 SARS-CoV-2 复制和与宿主组织的结合。18伊维菌素具有有效的抗炎特性，体外数据表明对细胞因子产生和核因子-κB (NF-κB) 转录的显着抑制，核因子-κB (NF-κB) 是最有效的炎症介质。37 – 39当感染 SARS-CoV-2 或类似冠状病毒时，伊维菌素可显着降低病毒载量并保护多种动物模型免受器官损伤。31 , 32伊维菌素可防止接触受感染患者的人传播和发展 COVID-19 疾病。40 – 45伊维菌素可加速症状后早期治疗的轻度至中度疾病患者的康复并防止病情恶化。45 , 49 – 52 , 61 , 62伊维菌素可加速住院患者的康复并避免入住 ICU 和死亡。45 , 51 , 53 , 63 – 66伊维菌素可降低 COVID-19 重症患者的死亡率。45 , 53 , 63在伊维菌素分发活动之后，伊维菌素导致各地区病死率的时间相关降低。48伊维菌素的安全性、可用性和成本几乎是无与伦比的，因为其重要药物相互作用的发生率很低，并且在近 40 年的使用和数十亿剂的给药中仅观察到轻微和罕见的副作用。75世界卫生组织长期以来一直将伊维菌素列入其“基本药物清单”。经过一段时间的讨论后，根据标准的 WHO 指南制定流程，对伊维菌素数据的多个方面进行了投票。小组发现伊维菌素对生存影响的证据确定性很强，他们建议无条件采用用于 COVID-19 的预防和治疗。 综上所述，根据本次审查中提供的全部试验和流行病学证据，以及 Unitaid/WHO 对治疗 RCT 的荟萃分析的初步结果和国际 BIRD 会议的指南建议，伊维菌素应在全球范围内系统地部署在预防和治疗 COVID-19 方面。 The Panel found the certainty of evidence for ivermectin's effects on survival to be strong and they recommended unconditional adoption for use in the prophylaxis and treatment of COVID-19. In summary, based on the totality of the trials and epidemiologic evidence presented in this review along with the preliminary findings of the Unitaid/WHO meta-analysis of treatment RCTs and the guideline recommendation from the international BIRD conference, ivermectin should be globally and systematically deployed in the prevention and treatment of COVID-19. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088823/ 
Conclusions: Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally. 结论： 中等质量证据发现，使用伊维菌素可以大幅减少 COVID-19 死亡人数。在临床过程早期使用伊维菌素可能会减少进展为严重疾病的人数。明显的安全性和低成本表明，伊维菌素可能对全球SARS-CoV-2大流行产生重大影响。 DISCUSSIONThe findings indicate with moderate certainty that ivermectin treatment in COVID-19 provides a significant survival benefit. Our certainty of evidence judgment was consolidated by the results of trial sequential analyses, which show that the required IS has probably already been met. Low-certainty evidence on improvement and deterioration also support a likely clinical benefit of ivermectin. Low-certainty evidence suggests a significant effect in prophylaxis. Overall, the evidence also suggests that early use of ivermectin may reduce morbidity and mortality from COVID-19. This is based on (1) reductions in COVID-19 infections when ivermectin was used as prophylaxis, (2) the more favorable effect estimates for mild to moderate disease compared with severe disease for death due to any cause, and (3) on the evidence demonstrating reductions in deterioration. 讨论研究结果中度确定地表明，伊维菌素治疗 COVID-19 提供了显着的生存益处。试验顺序分析的结果巩固了我们对证据判断的确定性，这表明可能已经满足了所需的 IS。关于改善和恶化的低质量证据也支持伊维菌素可能的临床益处。低质量证据表明在预防方面有显着效果。总体而言，证据还表明，早期使用伊维菌素可能会降低 COVID-19 的发病率和死亡率。这是基于 (1) 使用伊维菌素预防时 COVID-19 感染减少，(2) 与严重疾病相比，由于任何原因导致的死亡，轻度至中度疾病的效果估计更有利， 本综述中严重不良事件的证据被评为低质量，部分原因是事件太少而无法达到统计学意义。最近对寄生虫感染患者使用伊维菌素进行系统评价的证据表明，以常规剂量（0.2 或 0.4 mg/kg）施用伊维菌素是安全的，并且在更高剂量下可能是安全的。7,116世界卫生组织最近一份关于伊维菌素用于疥疮的文件发现，伊维菌素的不良事件主要是轻微和短暂的。22 
https://journals.lww.com/americantherapeutics/fulltext/2021/08000/ivermectin_for_prevention_and_treatment_of.7.aspx 这是伊维菌素： 
这才是土霉素： 
|
